Elite Pharmaceuticals, Inc. (OTCBB:ELTP) Conquers All-Time High on Optimistic Momentum
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) is enjoying enough loyalty and enthusiasm, as it added more than 34% to 33 cents on dollar volumes of $5.5 million. ELTP was one of the many tickers which shot through the roof, after being pressured down ahead of the long weekend. 
But ELTP is still under the spell of a $100,000 promotion from Stockpalooza.com, and it is possible that new emails or PR lift it higher. ELTP started a new trial for its anti-opioid treatment, which will bring some expectation of results, and increase activity in the following months. ELTP, despite its solid background, remains ridden by the problems of most pharmaceutical companies- the fatigue of investors to wait out the stagnant times. But the good news are also trouble, since they often cause disproportionate, short-term spikes.
Investors’ forums are indeed hopeful the company would be providing new soon, which would bring it to a higher range. Also, long-term investors are patting themselves on the back for holding out, as only a month ago ELTP had little to show in terms of upward momentum.
Natural Health Trends, Corp. (OTCMKTS:NHTC) is yet another long-term climber in the pharmaceutical sector which gained attention faster in the past weeks, making a steeper run. NHTC reached $3.47, after bucking the trend just at the threshold level of $4.
Another strong contender in the anti-opioid treatments is Titan Pharmaceuticals, Inc. (OTCBB:TTNP), which is working on a novel mode of implant-delivered substances. It was precisely the implants that caused trouble and so far have not gained acceptance from the FDA until further testing and proofs of efficiency. Still, TTNP is making a recovery in the past days, accelerating its gains toward the 73-cent levels. In the past, TTNP has attacked the dollar price confidently and quickly, on many rounds, but also lived through painful gaps or corrections.
In the case of ELTP, the current price is an all-time high. The clustering of high volumes has not been seen since 2011, when the spring months arrived with an emailed promotion that lifted up the shares. So keep in mind that ELTP rises on a pair of factors- the slower driving factor is the company’s natural business development, but email campaigns cause the truly steep gains. Unfortunately, in the past the losses after the campaigns ended reached as far as 60%, which though not as catastrophic as for other tickers is still rather painful.
If you still like ELTP, keep in mind that the OTC markets are generally favoring the pharma sector in the initial months of the new year, which are thick with company messages and outlooks on the year ahead.
